ANI Pharmaceuticals ANIP Generics and Other — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's generics and other — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's generics and other — operating income (loss)?
- ANI Pharmaceuticals (ANIP) reported generics and other — operating income (loss) of $40.32M in Q1 2026.
- How has ANI Pharmaceuticals's generics and other — operating income (loss) changed year-over-year?
- ANI Pharmaceuticals's generics and other — operating income (loss) decreased by 16.9% year-over-year, from $48.54M to $40.32M.
- What is the long-term trend for ANI Pharmaceuticals's generics and other — operating income (loss)?
- Over 3 years (2022 to 2025), ANI Pharmaceuticals's generics and other — operating income (loss) has grown at a 21.9% compound annual growth rate (CAGR), from $85.48M to $154.99M.
- What does generics and other — operating income (loss) mean?
- Measures the profitability of the generics segment by subtracting operating expenses from net revenues, excluding interest and taxes. It serves as the core indicator of the segment's operational performance and its ability to generate sustainable earnings from its primary business activities.